JSKN003 Versus Trastuzumab Emtansine (T-DM1) for HER2-Positive, Advanced Breast Cancer

NCT06846437 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

228

Enrollment

INDUSTRY

Sponsor class

Conditions

Unrespectable Locally Advanced and or Metastatic HER2 Positive Breast Cancer Participants

Interventions

DRUG: JSKN003
DRUG: Trastuzumab emtansine (T-DM1)

Sponsor

Shanghai JMT-Bio Inc.